NCT03975647 2025-12-10
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03571633 2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2 Active not recruiting
NCT03738553 2025-10-29
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
Active not recruiting
NCT06316531 2025-08-19
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06968585 2025-05-13
A166
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Active not recruiting
NCT03460067 2025-03-27
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
University of Kansas Medical Center
Phase NA Active not recruiting